Age
Item
1. age 18 years or older at the time of screening.
boolean
C0001779 (UMLS CUI [1])
Informed Consent | Informed Consent Patient Representative
Item
2. subject/legal representative willing and able to provide written informed consent.
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C0030701 (UMLS CUI [2,2])
Diffuse Large B-Cell Lymphoma | Follicular Lymphoma Transformation Diffuse Large B-Cell Lymphoma
Item
3. histologically confirmed aggressive b-cell dlbcl, including fl transforming to dlbcl.
boolean
C0079744 (UMLS CUI [1])
C0024301 (UMLS CUI [2,1])
C0040682 (UMLS CUI [2,2])
C0079744 (UMLS CUI [2,3])
Diffuse large B-cell lymphoma recurrent Tumor tissue sample
Item
4. willing to provide existing relapse-confirmatory dlbcl tumor sample.
boolean
C0855111 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
Recurrent disease | Refractory Disease | Combined Modality Therapy | rituximab | Chemotherapy Anthracyclines Based
Item
5. relapsed from or refractory to at least one treatment containing rituximab combined with anthracycline-based chemotherapy.
boolean
C0277556 (UMLS CUI [1])
C1514815 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
C0393022 (UMLS CUI [4])
C0392920 (UMLS CUI [5,1])
C0282564 (UMLS CUI [5,2])
C1705938 (UMLS CUI [5,3])
Lesion Quantity Long axis CT scan | Lesion Quantity Short axis CT scan
Item
6. ct scans showing involvement of 1 or more clearly demarcated lesions with a long axis > 1.5 cm and short axis >/=1.0 cm.
boolean
C0221198 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0522487 (UMLS CUI [1,3])
C0040405 (UMLS CUI [1,4])
C0221198 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0522488 (UMLS CUI [2,3])
C0040405 (UMLS CUI [2,4])
Hypermetabolism FDG-PET CT Scan
Item
7. baseline fdg pet/ct scans must demonstrate at least one hypermetabolic lesion as defined by the deauville criteria (52) localizing to ct-defined anatomical tumor sites.
boolean
C0342952 (UMLS CUI [1,1])
C4521453 (UMLS CUI [1,2])
Patient Appropriate High-dose chemotherapy | Patient Appropriate Transplantation of autologous hematopoietic stem cell
Item
8. suitable candidate for therapy with high-dose chemotherapy and asct as determined by the treating physician.
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C1328050 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C1548787 (UMLS CUI [2,2])
C1831743 (UMLS CUI [2,3])
ECOG performance status
Item
9. eastern cooperative oncology group (ecog) performance status of 0, 1, or 2.
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
10. life expectancy of >/=12 weeks as estimated by the treating physician.
boolean
C0023671 (UMLS CUI [1])
Childbearing Potential Serum pregnancy test (B-HCG) Negative
Item
11. negative serum beta-human chorionic gonadotropin (beta-hcg) test (women of childbearing potential only).
boolean
C3831118 (UMLS CUI [1,1])
C0430060 (UMLS CUI [1,2])
C1513916 (UMLS CUI [1,3])
Organ function | Creatinine measurement, serum | Estimation of creatinine clearance by Cockcroft-Gault formula
Item
12. adequate organ function defined as follows: serum creatinine </= 1.5 × uln or calculated creatinine clearance (crcl) >/= 50 ml/min as determined by the cockcroft-gault equation.
boolean
C0678852 (UMLS CUI [1])
C0201976 (UMLS CUI [2])
C2711451 (UMLS CUI [3])
Condition Interferes with Interpretation Research results | Condition Interferes with Patient safety | Sarcoidosis | Granulomatous disorder
Item
1. any condition that, in the opinion of the investigator, would interfere with the interpretation of study results or subject safety including non-malignant fdg avid diseases such as sarcoidosis or other granulomatous disease.
boolean
C0348080 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0459471 (UMLS CUI [1,3])
C0683954 (UMLS CUI [1,4])
C0348080 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C1113679 (UMLS CUI [2,3])
C0036202 (UMLS CUI [3])
C0740451 (UMLS CUI [4])
Diabetic - poor control
Item
2. uncontrolled diabetes mellitus.
boolean
C0421258 (UMLS CUI [1])
Study Subject Participation Status | Chemotherapy Except Standard therapy
Item
3. concurrent enrollment in another clinical study where they are receiving non-standard salvage chemotherapy, (i.e., concurrent enrollment is allowable if the patient is receiving standard salvage chemotherapy and research imaging is allowed).
boolean
C2348568 (UMLS CUI [1])
C0392920 (UMLS CUI [2,1])
C0332300 (UMLS CUI [2,2])
C2936643 (UMLS CUI [2,3])
Hypersensitivity Serious Component Rice | Allergic Reaction Serious Component Rice | Other Coding
Item
4. history of serious allergy or reaction to any component of rice or rdhap formulations that would prevent administration.
boolean
C0020517 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C1705248 (UMLS CUI [1,3])
C0035567 (UMLS CUI [1,4])
C1527304 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
C1705248 (UMLS CUI [2,3])
C0035567 (UMLS CUI [2,4])
C3846158 (UMLS CUI [3])